公開日期 | 標題 | 作者 | 來源出版物 | scopus | WOS | 全文 |
2009 | National Center of Excellence for Clinical Trials and Research at National Taiwan University Hospital | CHIA-CHI LIN ; CHIH-HSIN YANG ; ANN-LII CHENG ; Chan W.-K.; HONG-NERNG HO | Drug Information Journal | 3 | 2 | |
2022 | Nazartinib for treatment-naive EGFR-mutant non-small cell lung cancer: Results of a phase 2, single-arm, open-label study | Tan, Daniel S W; Kim, Sang-We; Ponce Aix, Santiago; Sequist, Lecia V; Smit, Egbert F; CHIH-HSIN YANG ; Hida, Toyoaki; Toyozawa, Ryo; Felip, Enriqueta; Wolf, Juergen; Grohé, Christian; Leighl, Natasha B; Riely, Gregory; Cui, Xiaoming; Zou, Mike; Ghebremariam, Samson; O'Sullivan-Djentuh, Leslie; Belli, Riccardo; Giovannini, Monica; Kim, Dong-Wan | European journal of cancer (Oxford, England : 1990) | 4 | 4 | |
2013 | Neoadjuvant chemotherapy with docetaxel-cisplatin in patients with stage III N2 non-small-cell lung cancer | WEI-YU LIAO ; Chen J.-H.; Wu M.; JIN-YUAN SHIH ; KUAN-YU CHEN ; CHAO-CHI HO ; CHIH-HSIN YANG ; CHONG-JEN YU | Clinical Lung Cancer | 22 | 20 | |
2017 | New data on clinical decisions in NSCLC patients with uncommon EGFR mutations | Wu T.; Hsiue E.H.; JIH-HSIANG LEE ; Chia-Chi Lin ; CHIH-HSIN YANG | Expert Review of Respiratory Medicine | 15 | 14 | |
2020 | Nivolumab safety and efficacy in advanced, platinum-resistant, non-small cell lung cancer, radical radiotherapy-ineligible patients: A phase II study in Taiwan | Chen Y.-M.; CHIH-HSIN YANG ; Su W.-C.; Chong I.-W.; Hsia T.-C.; Lin M.-C.; Chang G.-C.; Chiu C.-H.; CHAO-CHI HO ; Wu S.-Y.; Hung J.-Y.; Wang C.-C.; Yang T.-Y.; CHONG-JEN YU | Journal of the Formosan Medical Association | 8 | 5 | |
2012 | Nomogram to predict the presence of EGFR activating mutation in lung adenocarcinoma | Girard N; Sima C.S; Jackman D.M; Sequist L.V; Chen H; CHIH-HSIN YANG ; Ji H; Waltman B; Rosell R; Taron M; Zakowski M.F; Ladanyi M; Riely G; Pao W. | European Respiratory Journal | 75 | 90 | |
2013 | Norcantharidin suppresses cell growth and migration with enhanced anticancer activity of gefitinib and cisplatin in human non-small cell lung cancer cells | Lee Y.-C; Lee L.-M; CHIH-HSIN YANG ; Lin A.M.-Y; Huang Y.-C; Hsu C.-C; Chen M.-S; Chi C.-W; Yin P.-H; Kuo C.-D; Liao J.-F; Lee H.-C. | Oncology Reports | 22 | 17 | |
2017 | Novel EGFR Inhibitors in Non-small Cell Lung Cancer: Current Status of Afatinib | BIN-CHI LIAO ; CHIA-CHI LIN ; CHIH-HSIN YANG | Current Oncology Reports | 19 | 19 | |
2003 | Novobiocin sensitizes BCRP/MXR/ABCP overexpressing topotecan-resistant human breast carcinoma cells to topotecan and mitoxantrone | CHIH-HSIN YANG ; YAO-CHANG CHEN ; Kuo M.-L. | Anticancer Research | 36 | 28 | |
2010 | O6-Methylguanine-DNA methyltransferase expression and prognostic value in brain metastases of lung cancers | PEI-FANG WU; KUAN-TING KUO ; LU-TING KUO ; YI-TING LIN; WEI-CHUNG LEE; YEN-SHEN LU ; CHIH-HSIN YANG ; RUEY-MEEI WU ; YONG-KWANG TU ; JUI-CHANG TASI ; HAM-MIN TSENG; SHENG-HONG TSENG ; ANN-LII CHENG ; CHING-HUNG LIN | Lung Cancer | 26 | 26 | |
2010 | Octogenarians with advanced non-small cell lung cancer: Treatment modalities, survival, and prognostic factors | KUAN-YU CHEN ; JEN-HAU CHEN ; JIN-YUAN SHIH ; CHIH-HSIN YANG ; CHONG-JEN YU ; PAN-CHYR YANG | Journal of Thoracic Oncology | 17 | 14 | |
2019 | Opportunities of circulating tumor DNA in lung cancer | Wu T.-H; Hsiue E.H.-C; CHIH-HSIN YANG | Cancer Treatment Reviews | 14 | 14 | |
2017 | Optimal management of EGFR-mutant non-small cell lung cancer with disease progression on first-line tyrosine kinase inhibitor therapy | BIN-CHI LIAO ; Chia-Chi Lin ; JIH-HSIANG LEE ; CHIH-HSIN YANG | Lung Cancer | 38 | 35 | |
2011 | Optimal management of patients with non-small cell lung cancer and epidermal growth factor receptor mutations | CHIA-CHI LIN ; CHIH-HSIN YANG | Drugs | 10 | 10 | |
2023 | Osimertinib + Savolitinib to Overcome Acquired MET-Mediated Resistance in Epidermal Growth Factor Receptor-Mutated, MET-Amplified Non-Small Cell Lung Cancer: TATTON | Hartmaier, Ryan J; Markovets, Aleksandra A; Ahn, Myung Ju; Sequist, Lecia V; Han, Ji-Youn; Cho, Byoung Chul; Yu, Helena A; Kim, Sang-We; CHIH-HSIN YANG ; Lee, Jong-Seok; Su, Wu-Chou; Kowalski, Dariusz M; Orlov, Sergey; Ren, Song; Frewer, Paul; Ou, Xiaoling; Cross, Darren A E; Kurian, Nisha; Cantarini, Mireille; Jänne, Pasi A | Cancer discovery | 36 | 29 | |
2018 | Osimertinib as first-line treatment of EGFR mutation-positive advanced non-small-cell lung cancer | Ramalingam S.S; CHIH-HSIN YANG ; Lee C.K; Kurata T; Kim D.-W; John T; Nogami N; Ohe Y; Mann H; Rukazenkov Y; Ghiorghiu S; Stetson D; Markovets A; Barrett J.C; Thress K.S; Jänne P.A. | Journal of Clinical Oncology | 401 | 346 | |
2023 | Osimertinib for EGFR-Mutant Non-Small-Cell Lung Cancer Central Nervous System Metastases: Current Evidence and Future Perspectives on Therapeutic Strategies | Popat, Sanjay; Ahn, Myung-Ju; Ekman, Simon; Leighl, Natasha B; Ramalingam, Suresh S; Reungwetwattana, Thanyanan; Siva, Shankar; Tsuboi, Masahiro; Wu, Yi-Long; CHIH-HSIN YANG | Targeted oncology | 2 | 5 | |
2020 | Osimertinib in patients with epidermal growth factor receptor mutation-positive non-small-cell lung cancer and leptomeningeal metastases: The BLOOM study | CHIH-HSIN YANG ; Kim, Sang-We; Kim, Dong-Wan; Lee, Jong-Seok; Cho, Byoung Chul; Ahn, Jin-Seok; Lee, Dae H.; Kim, Tae Min; Goldman, Jonathan W.; Natale, Ronald B.; Brown, Andrew P.; Collins, Barbara; Chmielecki, Juliann; Vishwanathan, Karthick; Mendoza-Naranjo, Ariadna; Stathes Paganis | Journal of Clinical Oncology | 213 | 189 | |
2019 | Osimertinib in patients with T790M mutation-positive, advanced non–small cell lung cancer: Long-term follow-up from a pooled analysis of 2 phase 2 studies | Ahn M.-J; Tsai C.-M; Shepherd F.A; Bazhenova L; Sequist L.V; Hida T; CHIH-HSIN YANG ; Ramalingam S.S; Mitsudomi T; Jnne P.A; Mann H; Cantarini M; Goss G. | Cancer | 120 | 111 | |
2020 | Osimertinib in patients with T790M-positive advanced non-small cell lung cancer: Korean subgroup analysis from phase II studies | Ahn M.-J.; Han J.-Y.; Kim D.-W.; Cho B.C.; Kang J.-H.; Kim S.-W.; CHIH-HSIN YANG ; Mitsudomi T.; Lee J.S. | Cancer Research and Treatment | 5 | 5 | |